By Turna Ray

Qiagen's proposed acquisition of Australian testmaker Cellestis would give the firm a test portfolio that will work in concert with its existing tests and allow it to improve diagnostics for preventing disease and personalizing care.

The A$341 million ($355 million) acquisition plan, announced this week, is still subject to approval by Cellestis' shareholders. Qiagen projects that the transaction will be approved in June, when Cellestis' shareholders are scheduled to meet.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.